




PHARMACEUTICAL 2021

Scopus BioPharma Inc.
Rank 392 of 402





PHARMACEUTICAL 2021

Scopus BioPharma Inc.
Rank 392 of 402

The relative strengths and weaknesses of Scopus BioPharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Scopus BioPharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Scopus BioPharma Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 337% points.

The company's Economic Capital Ratio, given in the ranking table, is -485%, being 533% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	1,972
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,805
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-35
Other Expenses	706
Other Liabilities	0
Other Net Income	0
Other Revenues	0
Property and Equipment	2.3
Research and Development	7,424
Selling, General and Administrative Expense	2,732

Output Variable	Value in 1000 USD
Assets	1,974
Liabilities	3,805
Expenses	10,862
Revenues	0
Stockholders Equity	-1,831
Net Income	-10,862
Comprehensive Net Income	-10,880
Economic Capital Ratio	-485%